Tagged with Research,

UK Keith Thompson, CEO of the Cell & Gene Therapy Catapult, one of a number of Catapult institutions in the UK designed to help commercialize innovative research, discusses strategy, funding, international collaboration and Brexit.     Most likely, the UK is the best environment for putting forward trials that are properly…

UK Sir John Savill, chief executive of the Medical Research Council between 2010 and 2018, discusses the organization’s transition into part of the new UK Research and Innovation (UKRI) grouping, the highlights of his tenure in terms of medical research in the UK, and the potential pitfalls of the Brexit process.…

India The global pharmaceutical outsourcing market was estimated to be USD 115.7 billion in 2016, of which 49 percent is accounted for by contract research organisations (CROs). Within India, the contract research market is scheduled to grow from around USD one billion in 2016 to USD 1.97 billion by 2023 according…

UK Steve Ford, CEO of Parkinson’s UK, one of the UK’s leading research-based charities, discusses his organization’s recent Digital Leadership Award, presenting the needs of Parkinson’s patients to stakeholders, and why the UK will remain a leading research hub in the years to come.   One of our key challenges is…

UK Tony Jones, CEO of One Nucleus, a life sciences membership organization centered on the Greater London-Cambridge-East of England corridor, discusses the role of SMEs within the UK’s healthcare ecosystem, translational research, and how the association’s members will navigate the post-Brexit landscape in the UK.  One Nucleus, which was established in…

Portugal Portugal’s Minister for Science, Technology and Higher Education, Manuel Heitor, details his plan to bring Portuguese scientific and business practices above European averages. Collaboration across industries, increased public and private investment into R&D and innovative global projects will pave the way for Portugal’s progression in Europe. Can you please outline…

UK Sir John Chisholm, executive chair of Genomics England – a company set up and owned by the UK Department of Health to run the 100,000 Genomes Project, which aims to sequence 100,000 genomes from NHS patients with a rare disease and their families, and patients with cancer – discusses the…

Portugal The iMM (Instituto de Medicina Molecular) is a leading Portuguese private non-profit research institute that offers a vibrant scientific environment, aiming to nurture innovative ideas in basic, clinical and translational biomedical research. Maria Mota approaches her fifth year of leadership at IMM, where she has made it her intention to emphasize…

UK Michelle Mitchell, CEO of the Multiple Sclerosis Society in the UK since 2013, discusses her charity’s aims; their focus on research and development; funding in the face of Brexit; and policy changes in the future.   Although the MS community is fairly small, the science is telling us that with…

UK Recipient of the 2018 Brain Prize for research for groundbreaking research on the generic and molecular basis of Alzheimer’s Disease, the UCL’s Professor John Hardy discusses recent progress in dementia research, the strengths and weaknesses of the UK’s medical research environment, and the potential effects of Brexit.   In all…

Ecuador Tania Mori Lucero, executive director of the Ecuadorian National Institute of Public Research (INSPI), details the entity’s role in supporting the elaboration of public health policies under the Ministry of Public Health’s umbrella. Mori highlights the important progress that has been made in the country’s research ecosystem and documents the…

Canada Upon opening an R&D center in Mississauga in 2017, Biolab Pharma Canada, headed by Paulo Wickbold Marques, became the first Brazilian pharmaceutical company to establish an affiliate in Canada. In this interview, Paulo describes Biolab’s bold leap from Latin America, the strengths of the Canadian pharmaceutical landscape and how the…